There are 140 resources available
40MO - First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status
Presenter: Els Van Nieuwenhuysen
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 35MO+36MO, 37MO, 38MO, 39MO and 40MO
Presenter: Ramez Eskander
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast
82MO - European multi-disciplinary tumor boards within the EURACAN network increasingly support management of patients with rare gynaecological tumors: 6-year activity results
Presenter: Alice Bergamini
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
45MO - Management of stage I ovarian Sertoli-Leydig cell tumors: Prognostic factors from a multicenter international retrospective study
Presenter: Giovanna Scarfone
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 82MO and 45MO
Presenter: Jubilee Brown
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast
Introduction
Presenter: Domenica Lorusso
Session: Keynote lecture
Resources:
Slides
Webcast
10 years of success in gynaecological malignancies treatment: Moving forward into a brilliant future
Presenter: GIOVANNI Scambia
Session: Keynote lecture
Resources:
Slides
Webcast
Introduction
Presenter: Sandro Pignata
Session: GSK - Paradigm shifts and improving outcomes for patients with dMMR/MSI-H endometrial cancer
Resources:
Webcast